Drug Trial Radar · NCT06741644
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Feb 24, 2025
Primary completion
Jan 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- CStone PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a Phase I dose escalation and Phase II dose expansion.
Conditions
- Advanced Solid Tumors
Interventions
CS2009Drug
CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).
CS2009Drug
CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 14/21-day cycles (Q2W/Q3W).
PemetrexedDrug
IV infusion
CarboplatinDrug
IV infusion
PaclitaxelDrug
IV infusion
EtoposideDrug
IV infusion
Nab-paclitaxelDrug
IV infusion
OxaliplatinDrug
IV infusion
CapecitabineDrug
oral tablets
DocetaxelDrug
IV infusion
LeucovorinDrug
IV infusion
5-FUDrug
IV infusion
CisplatinDrug
IV infusion
GemcitabineDrug
IV infusion
IrinotecanDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Dose Escalation] Maximum tolerated dose (MTD) of CS2009Time frame: Cycle 1 (Up to 21 Days)
- [Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS2009Time frame: Cycle 1 (Up to 21 Days)
- [Dose Escalation] Number of participants with adverse events (AEs)Time frame: Up to approximately 2 years
- [Dose Expansion] Objective response rate (ORR) evaluated by investigators per RECIST v1.1Time frame: Up to approximately 2 years
Locations
33 sites in 3 countries. Site status is shown where the registry gives one.
START Los Angeles, LLC
Los Angeles, California · Recruiting
NEXT Dallas
Irving, Texas · Recruiting
Alfred Hospital (Alfred Health)
Melbourne, Australia · Recruiting
Austin Hospital (Austin Health)
Melbourne, Australia · Recruiting
Monash Medical Centre (Monash Health)
Melbourne, Australia · Recruiting
Peter Maccallum Cancer Centre Research
Melbourne, Australia · Recruiting
Icon Cancer Centre South Brisbane
South Brisbane, Australia · Recruiting
Blacktown Hospital
Sydney, Australia · Recruiting
Macquarie University Hospital
Sydney, Australia · Recruiting
Scientia Clinical Research Ltd
Sydney, Australia · Recruiting
Beijing Cancer Hospital
Beijing, China · Recruiting
Jilin Cancer Hospital
Changchun, China · Recruiting
Hunan Cancer Hospital
Changsha, China · Recruiting
Sichuan Cancer Hospital
Chengdu, China · Recruiting
West China Hospital of Sichuan University
Chengdu, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China · Recruiting
Sun Yat-Sen University Cancer Center
Guangzhou, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Recruiting
Anhui Provincial Hospital
Hefei, China · Recruiting
Central Hospital Affiliated to Shandong First Medical University
Jinan, China · Recruiting
Linyi Cancer Hospital
Linyi, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Shanghai East Hospital
Shanghai, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China · Recruiting
Xuzhou Central Hospital
Xuzhou, China · Recruiting
Henan Cancer Hospital
Zhengzhou, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.